Amicus Therapeutics (NASDAQ:FOLD) Now Covered by Analysts at Citigroup

Citigroup started coverage on shares of Amicus Therapeutics (NASDAQ:FOLD) in a research report report published on Wednesday morning, MarketBeat.com reports. The firm issued a buy rating and a $17.00 price objective on the biopharmaceutical company’s stock.

A number of other research firms also recently issued reports on FOLD. Weiss Ratings restated a “sell (d-)” rating on shares of Amicus Therapeutics in a research note on Monday. Zacks Research raised Amicus Therapeutics from a “hold” rating to a “strong-buy” rating in a report on Monday, October 6th. Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Needham & Company LLC upgraded shares of Amicus Therapeutics from a “hold” rating to a “buy” rating and set a $14.00 price target for the company in a research report on Thursday, September 18th. Finally, JPMorgan Chase & Co. upped their price target on shares of Amicus Therapeutics from $18.00 to $19.00 and gave the company an “overweight” rating in a research report on Thursday, November 6th. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $17.29.

Amicus Therapeutics Price Performance

Shares of NASDAQ:FOLD opened at $11.00 on Wednesday. Amicus Therapeutics has a 12 month low of $5.51 and a 12 month high of $11.14. The firm has a market capitalization of $3.39 billion, a P/E ratio of -274.93 and a beta of 0.46. The company has a debt-to-equity ratio of 1.70, a current ratio of 2.99 and a quick ratio of 2.09. The company’s fifty day moving average price is $9.31 and its 200 day moving average price is $7.75.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, November 4th. The biopharmaceutical company reported $0.17 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.12 by $0.05. Amicus Therapeutics had a negative net margin of 2.35% and a positive return on equity of 6.95%. The company had revenue of $169.06 million during the quarter, compared to the consensus estimate of $165.24 million. During the same quarter in the prior year, the firm posted $0.10 earnings per share. Amicus Therapeutics’s revenue for the quarter was up 19.5% on a year-over-year basis. As a group, sell-side analysts predict that Amicus Therapeutics will post 0.15 earnings per share for the current fiscal year.

Insider Buying and Selling

In other Amicus Therapeutics news, insider Ellen Rosenberg sold 23,621 shares of the company’s stock in a transaction on Wednesday, November 26th. The shares were sold at an average price of $10.00, for a total transaction of $236,210.00. Following the completion of the transaction, the insider owned 507,710 shares in the company, valued at approximately $5,077,100. This represents a 4.45% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bradley L. Campbell sold 77,926 shares of Amicus Therapeutics stock in a transaction dated Monday, December 15th. The shares were sold at an average price of $10.86, for a total transaction of $846,276.36. Following the completion of the sale, the chief executive officer directly owned 1,129,782 shares in the company, valued at approximately $12,269,432.52. The trade was a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 319,808 shares of company stock valued at $3,293,653 in the last ninety days. Company insiders own 2.20% of the company’s stock.

Institutional Investors Weigh In On Amicus Therapeutics

A number of hedge funds have recently added to or reduced their stakes in FOLD. Osaic Holdings Inc. boosted its holdings in Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 3,358 shares in the last quarter. EverSource Wealth Advisors LLC raised its stake in shares of Amicus Therapeutics by 472.6% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 3,677 shares in the last quarter. Strs Ohio acquired a new stake in shares of Amicus Therapeutics in the 1st quarter valued at approximately $30,000. ANTIPODES PARTNERS Ltd purchased a new stake in shares of Amicus Therapeutics in the third quarter valued at approximately $31,000. Finally, Allworth Financial LP grew its holdings in Amicus Therapeutics by 36.3% during the third quarter. Allworth Financial LP now owns 4,678 shares of the biopharmaceutical company’s stock worth $37,000 after acquiring an additional 1,246 shares during the period.

Amicus Therapeutics Company Profile

Amicus Therapeutics, Inc, a biotechnology company, focuses on discovering, developing, and delivering medicines for rare diseases. Its commercial product and product candidates include Galafold, an oral precision medicine for the treatment of adults with a confirmed diagnosis of Fabry disease and an amenable galactosidase alpha gene variant; and Pombiliti + Opfolda, for the treatment of late onset.